


## Three Omicron scenarios for the global economy

Nobody knows if the new variant will be more transmissible or deal a significant blow to the current vaccines. These are the best and worst outcomes for the global economy



Immunofluorescence staining of Omicron infected cells in Hong Kong

Very little is known about the new Omicron variant, at the time of writing. Data is scarce, but we know what happens next depends heavily on two key questions. First, is the virus more transmissible, as some early reports have hinted? And second – perhaps more importantly for the economic outlook at least – how resistant is the new variant to vaccines and pre-existing immunity?

We've mapped out three scenarios based on the answers to those questions.

## Three Omicron scenarios for the global economy

| Omicron assumptions                                      |  |  |  |   |  |
|--|--|--|--|---|--|
|  | Faster spread?   | Vaccines less effective?   | More serious illness?  | Economic impact   | Forecasts  |
| ①<br>Optimistic Omicron                                  | <b>No</b><br>Delta stays dominant or transmission advantage minimal      | <b>No</b><br>Vaccines work well, especially against serious illness                | <b>No</b><br>Milder illness aids path to normality (less relevant if Delta still dominant) | Recovery continues. Central banks tighten/taper further in December           | 2022 growth: US <b>5.8%</b> EZ <b>4.2%</b><br>End-2022 EUR/USD <b>1.05</b> |
| ② <b>Base case</b><br>Omicron 'difficult' not 'disaster' | <b>Yes</b><br>Increases pressure further where gaps in vaccination exist | <b>Yes – a bit</b><br>Reduced but reasonable protection against serious illness    | <b>No</b><br>Possibly milder but not the dominant driver of the scenario                   | Winter growth slows. Central banks pause but 2022 tightening largely on track | 2022 growth: US <b>4.4%</b> EZ <b>3.8%</b><br>End-2022 EUR/USD <b>1.10</b> |
| ③<br>Omicron a significant blow                          | <b>Yes</b><br>Increases pressure further where gaps in vaccination exist | <b>Yes – a lot</b><br>Serious dent to protection increases hospital pressure in Q1 | <b>Yes</b><br>Contrary to early signs, new variant is more deadly than Delta               | Lockdowns hit GDP (though less than 2021). Central bank tightening stops      | 2022 growth: US <b>1.3%</b> EZ <b>2.1%</b><br>End-2022 EUR/USD <b>1.20</b> |


Source: ING

### 1 Scenario 1: Optimistic Omicron

Omicron proves to be a 'storm in a teacup'. Either that's because it can't gain a foothold over Delta – something we saw with the Beta variant earlier in the year – or indeed because it lowers the threat level of Covid-19 by lowering the chances of severe disease.

This looks similar to our previous base case, and here central banks press on with their tightening plans. The Federal Reserve accelerates its taper in December and gears up for three rate hikes in 2022. Sporadic Delta lockdowns slow eurozone growth over Christmas and early into the new year, but the situation improves through the spring. The European Central Bank begins to taper amid growing wariness about inflation. The Bank of England kicks off its rate hike cycle this month.

#### Scenario 1 - Level of real GDP (Q419 = 100)



Source: Macrobond, ING

### 2 Scenario 2: Omicron 'difficult' but not a 'disaster'

This is loosely our base case. It assumes that early signs are correct that Omicron has a transmission advantage. That means a greater share of the population needs immunity to keep the virus under control. In practice, this threshold was already very high under Delta, but countries

with lower vaccine take-up in vulnerable groups face a greater challenge.


Vaccine efficacy also takes a hit, though as we saw with the Delta variant, the current jabs still provide strong (if reduced) protection against severe disease, even if they're much less likely to stop you from getting Covid altogether.

For the world economy, experience from the Delta wave last summer offers some clues. Omicron doesn't help Europe at a time of spiking cases and offers more justification for more aggressive action in the run-up to Christmas. But high vaccine rates and the arrival of boosters mean the continent (including the UK) comes off more lightly than other parts of the world. Consumer 'virus confidence' (eg appetite for socialising) need not take a permanent hit assuming vaccines still offer some reasonable protection.

The effect might be slightly more noticeable in the US, even if the bar for lockdowns is much higher. Lower vaccine rates (notably among vulnerable groups) could mean that confidence slips and activity levels take a hit, as we saw with Delta. Meanwhile, in Asia, Omicron stalls the move away from zero-Covid, especially in China. The recovery of supply chains is further delayed.

Central banks are likely to 'wait and see' in December, not least because it may be weeks before we know what we're dealing with. But inflation remains front and centre, so we should still expect some tightening of monetary policy next year.

## Scenario 2 - Level of real GDP (Q419 = 100)



Source: Macrobond, ING

## 3 Scenario 3 – Omicron deals significant blow to the recovery

This is the scenario markets were first worried about when the Omicron news first broke. Vaccines are significantly worse at stopping severe disease, making Europe and the US especially vulnerable to a fresh increase in hospitalisations, versus our other scenarios. We're also assuming Omicron ends up being more deadly too.

Countries that have relied most heavily on vaccines so far tighten restrictions. Europe returns to lockdowns in the first quarter, as do parts of the US.


That said, the economic hit is unlikely to be quite as bad as last winter. Most scientists agree that the current vaccines will still do something, even if considerably less than against Delta. And we know with reasonable certainty that a new vaccine can be made, albeit not rolled out much before the summer in large numbers. New anti-viral treatments will help too.

Protests in Europe also hint at some 'virus fatigue', making it politically challenging for governments to maintain strict restrictions for as long as last year. The second wave in early 2021 also showed that businesses are more geared up for tighter restrictions than when Covid first arrived. This is probably even more true now.

In short, we expect a dip in first-quarter GDP in the major developed economies, albeit not as deep as in early-2021. But the subsequent recovery could be gradual. A vaccine-resistant Omicron acts as a wake-up call that without more widespread vaccine manufacturing capability, future variants could deliver similar blows in subsequent winters.

Firms begin to factor this into their business decisions, limiting their appetite to invest. Consumers look to keep savings levels higher, in anticipation of future turbulence. Overall growth momentum proves more lacklustre through 2022, compared to the rapid rebounds we saw in Q2/3 2021.

### Scenario 3 - Level of real GDP (Q419 = 100)



### Authors

#### Carsten Brzeski

Global Head of Macro

[carsten.brzeski@ing.de](mailto:carsten.brzeski@ing.de)

#### James Smith

Developed Markets Economist

[james.smith@ing.com](mailto:james.smith@ing.com)

### Disclaimer

This publication has been prepared by the Economic and Financial Analysis Division of ING Bank N.V. ("ING") solely for information purposes without regard to any particular user's investment objectives, financial situation, or means. *ING forms part of ING Group (being for this purpose ING Group N.V. and its subsidiary and affiliated companies).* The information in the publication is not an investment recommendation and it is not investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Reasonable care has been taken to ensure that this publication is not untrue or misleading when published, but ING does not represent that it is accurate or complete. ING does not accept any liability for any direct, indirect or consequential loss arising from any use of this publication. Unless otherwise stated, any views, forecasts, or estimates are solely those of the author(s), as of the date of the publication and are subject to change without notice.

The distribution of this publication may be restricted by law or regulation in different jurisdictions and persons into whose

possession this publication comes should inform themselves about, and observe, such restrictions.

Copyright and database rights protection exists in this report and it may not be reproduced, distributed or published by any person for any purpose without the prior express consent of ING. All rights are reserved. ING Bank N.V. is authorised by the Dutch Central Bank and supervised by the European Central Bank (ECB), the Dutch Central Bank (DNB) and the Dutch Authority for the Financial Markets (AFM). ING Bank N.V. is incorporated in the Netherlands (Trade Register no. 33031431 Amsterdam). In the United Kingdom this information is approved and/or communicated by ING Bank N.V., London Branch. ING Bank N.V., London Branch is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. ING Bank N.V., London branch is registered in England (Registration number BR000341) at 8-10 Moorgate, London EC2 6DA. For US Investors: Any person wishing to discuss this report or effect transactions in any security discussed herein should contact ING Financial Markets LLC, which is a member of the NYSE, FINRA and SIPC and part of ING, and which has accepted responsibility for the distribution of this report in the United States under applicable requirements.

Additional information is available on request. For more information about ING Group, please visit <http://www.ing.com>.